35 results about "Eukaryotic translation" patented technology

A circular mRNA molecule possessing features resembling native mammalian mRNA demonstrates improved translation, while retaining the properties of an extremely long half-life inside cells. This circular mRNA is functional inside mammalian cells, being able to compete against native cellular mRNAs for the eukaryotic translation initiation machinery. The invention possesses additional RNA elements compared to a previous invention containing only an IRES element for successful in vitro or in vivo translation.

This application is directed generally to minicircle DNA vectors for the vaccination of foot-and-mouth disease (FMD). The transgene expression cassette in the minicircle DNA vector includes: a eukaryotic translation initiation nucleotide sequence, a mutant nucleotide sequence that encodes a foot-and-mouth disease virus (FMDV) capsid polyprotein precursor that contains at least one mutation to eliminate a restriction enzyme recognition site, a nucleotide sequence that encodes a protease that cleaves the FMDV capsid polyprotein precursor into a plurality of FMDV capsid proteins and a translational regulatory element to regulate the expression of the protease. The minicircle DNA vectors can be transfected directly into the cell of a mammalian host. When transfected into the mammalian host cell, virus-like particles can be produced intrinsically to stimulate the mammalian host's immune system to develop adaptive immunity toward foot-and-mouth disease.

A screening method for identifying compounds that alter the fidelity with which the initiation codon in mRNAs is recognized by the translational apparatus in eukaryotes is disclosed. This screening method was used to identify compounds having such activity. Methods of altering the fidelity of initiation codon selection are also disclosed. Methods of treating disorders characterized by single nucleotide mutations in initiation codons using compounds identified by the screening method, as well as methods of treating fungal and parasitic infections and hyperproliferative disorders using compounds identified by the screening method are also disclosed.

The invention belongs to the technical field of photodynamic gene therapy, and specifically relates to a photosensitizer-binding protein and polypeptide and applications thereof. The invention screens a photosensitizer binding protein from a human liver cDNA phage display library. The binding protein is human eukaryotic translation elongation factor eEF1A1 protein and its protein molecule with 70%-80% similarity in protein structure, and the photosensitizer binding polypeptide is eEF1A1 C-terminal 25aa and its 70%-80% similar amino acid sequence. The photosensitizer-binding protein can be combined with porphyrin-type photosensitizers in vitro, and has the function of enriching porphyrin-type photosensitizers in vivo, and transfects the photosensitizer-binding protein gene into various Mammalian cells, after artificial regulation and induction of expression, have a better photodynamic therapy effect. In addition, the photosensitizer-binding protein and polypeptide (PSP) provides a valuable reference for the development of photosensitizer prodrugs and the design of specific targeted photosensitizers.

The invention discloses applications of eukaryotic translation elongation factors in the breast cancer detection reagent, wherein the eukaryotic translation elongation factors comprise the eukaryotic translation elongation factor 1delta and the eukaryotic translation elongation factor 2. The invention further discloses the reagent for detecting the genotype of the susceptible SNP site of the eukaryotic translation elongation factors, and a kit prepared by adopting the reagent. Through the development and applications of the SNP biomarker of the eukaryotic translation elongation factors and the diagnostic kit, the diagnosis for breast cancer is convenient and feasible, a foundation is laid for clinicians to rapidly know the disease conditions of patients, and for evaluating the clinical treatment effects, and assistance is offered for searching for novel micromolecular drug targets with the potential treatment value.

The present application relates to papaya plants having increased resistance to the papaya ringspot virus as compared to a wild type plant due to a mutation in the eukaryotic translation initiation factor 4e and / or eukaryotic translation initiation factor iso4e gene leading to non-functional eukaryotic translation initiation factor 4e and / or eukaryotic translation initiation factor iso4e proteins. Methods of producing such papaya plants having increased resistance to the papaya ringspot virus are described.

The present invention discloses applications of EIF4G1 in diagnosis of squamous cell carcinomas, particularly uses of a eukaryotic translation initiation factor 4G1 (EIF4G1) gene or protein, or a detection reagent thereof, wherein the eukaryotic translation initiation factor 4G1 (EIF4G1) gene or protein, or detection reagent thereof is used for preparing a kit for determining whether tumors are non-small cell lung squamous cell carcinomas. In addition, experiment results show that EIF4G1 has a certain high expression in squamous cell carcinomas with different sources, such that EIF4G1 can be adopted as the marker of the squamous cell carcinoma pathological type so as to provide the accurate method for typing of different sources of cancers.

Provided are methods and compositions for inhibiting eukaryotic translation initiation factor. Such methods and compositions may be used alone or in conjunction with other therapies, such as gene therapies, for inhibiting cell proliferation and / or treating cancer.

The invention discloses a phosphorylated EIF5B specific antibody and its preparation method and application. The antibody is a polyclonal antibody of a human phosphorylated ElF5BT78 specific site. On the one hand, the antibody detects the expression of the phosphorylated EIF5BT78 site. It is possible to verify the relevant molecular mechanism. On the other hand, the antibody binds to the phosphorylated eukaryotic translation initiation factor 5B (p-EIF5B) protein, and a composition comprising this antibody is also provided. The present invention utilizes the existing phosphorylated protein Antibody technology, constructing a polyclonal antibody specific for phosphorylated EIF5BT78 site, which solves the problems of few types of EIF5B phosphorylated antibodies and poor specificity in the prior art, and provides the possibility for detecting the expression of phosphorylated EIF5BT78 site and verifying the relevant molecular mechanism .